tbuckley/cabot-search huggingface dataset:
FEASIBILITY OF IVUS-DERIVED FFR AS A NOVEL TECHNIQUE TO ESTIMATE FUNCTIONAL SEVERITY OF CORONARY STENOSIS: SYSTEMATIC EVALUATION OF THE METHODS TO DETERMINE THE REFERENCE LUMEN AREA FOR AUTOMATED FFR CALCULATION
Authors: Kuninobu Kashiyama, Shinjo Sonoda, Kozo Okada, Kensuke Matsushita, Kiyoshi Hibi, Brooke Hollak, Paul G. Yock, Alan Yeung, Peter Fitzgerald, Yasuhiro Honda
Journal: Journal of the American College of Cardiology (2020)
Correlations of patient-reported measures (PRM) for health, quality of life (QOL), functional status, and social supports with survival in early-stage colon cancer.
Authors: Annie Chen, Tina Hsu, Hagen F. Kennecke, Anky Lai, Leo Chen, Caroline Speers, Ryan Woods, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2013)

9577 Background: PRM can enhance our understanding of patients’ needs and facilitate cancer treatment decision making. Few studies have explored the relationships between brief PRM and outcomes in early stage colon cancer. Our aims were 1) to determine the effects of prospectively collected PRM on cancer-specific (CSS) and overall survival (OS) and 2) to examine if this association is modified in the elderly. Methods: Patients diagnosed with stage 1 to 3 colon cancer in 2008, evaluated at 1 of 5 regional cancer centers in British Columbia, and provided baseline PRM were included. PRM consisting of a series of short, self-administered scales that described patient-reported health, QOL, functional status and social supports were collected at baseline and correlated with CSS and OS using regression models that controlled for known prognostic factors such as tumor and nodal stage. We subsequently assessed for effect modification by age, stratifying the cohort into younger (YP; &lt;70 years) and elderly patients (EP; &gt;/=70 years). Results: In total, 223 patients were included: 94 (42%) were EP, 111 (49%) were women, and 152 (68%) were white. Compared to YP, EP were more frequently widowed (27 vs 9%, p=0.0005) and reported having children (92 vs 81%, p=0.03), but they were less likely to receive chemotherapy (57 vs 90%, p&lt;0.0001). There were no significant differences in PRM based on age, with the majority indicating they had regular contact with family and friends (92%) and many describing good overall health, QOL, and functional status (48, 61, and 69%, respectively). However, a significant proportion wished for more emotional support (54%). In regression models, self-reported poor functional status was associated with worse OS (HR 2.69, 95%CI 1.09-6.65), but not CSS (HR 1.74, 95%CI 0.61-4.94). This did not differ significantly between YP and EP (p interaction &gt;0.05). No other PRM correlated with OS or CSS (all p&gt;0.05). Conclusions: For early stage colon cancer, self-reported functional status was independently associated with OS. Additional PRM failed to enhance prognostication, suggesting that more comprehensive tools may be required to improve patient assessments.
IDIOPATHIC AORTITIS: AN ATYPICAL CASE ISOLATED TO THE CORONARY SINUS LEADING TO OBSTRUCTIVE CORONARY ARTERY DISEASE
Authors: Lekha Racharla, Preysi Patel, Tarick Sheikh, Kailyn Mann, Emilee Kurtz, Tyler Boozel, Amy M. Ahnert, Joanne Quinones
Journal: Journal of the American College of Cardiology (2020)
RISK OF HEART FAILURE WITH CARFILZOMIB IN PATIENTS WITH MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Pablo Paz, Wasawat Vutthikraivit, Barbara Mantilla, Saif El Nawaa, Sally Wongsanegsak, Mohamed Elmassry, M Rubayat Rahman, Ty Whisenant, Somedeb Ball
Journal: Journal of the American College of Cardiology (2020)
IMPLANTATION OF SELF-EXPANDING TRANSCATHETER HEART VALVES IN THE ANNULAR PLANE IS ASSOCIATED WITH LOW IMPLANT DEPTHS AND PACEMAKER RATES
Authors: Anthony David Pisaniello, Haytham B.E. Makki, Saleem Jahangeer, Matthew J. Daniels, Ragheb Hasan, Douglas G.W. Fraser
Journal: Journal of the American College of Cardiology (2020)
POTENTIAL UNREALIZED CARDIOVASCULAR BENEFIT OF NOVEL DIABETES AGENTS IN THE VETERANS HEALTH ADMINISTRATION SYSTEM: INSIGHT FROM THE CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM
Authors: Taufiq Salahuddin, Demetria McNeal, Vanessa Richardson, Javier Valle, Kamal Henderson, Sridharan Raghavan, David Saxon, Paul Hess, Michael Ho, Gregory G. Schwartz
Journal: Journal of the American College of Cardiology (2020)
A NOVEL PREDICTIVE MODEL FOR IN-HOSPITAL MORTALITY BASED ON BLOOD EXAMINATION IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Yuhei Goriki, Atsushi Tanaka, Astushi Kawaguchi, Kensaku Nishihira, Masahiro Natsuaki, Nozomi Watanabe, Keiichi Ashikaga, Nehiro Kuriyama, Yoshisato Shibata, Koichi Node
Journal: Journal of the American College of Cardiology (2020)
A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer
Authors: R. S. Herbst, D. S. Mendolson, S. Ebbinghaus, M. S. Gordon, P. O’Dwyer, G. Lieberman, J. Ing, R. Kurzrock, W. Novotny, G. Eckhardt
Journal: Journal of Clinical Oncology (2006)

3013 Background: Recombinant human Apo2L/TRAIL (rhApo2L) is the only dual pro-apoptotic receptor agonist that directly activates both pro-apoptotic receptors (DR4 &amp; DR5). RhApo2L selectively induces apoptosis (programmed cell death) in a variety of cancer cells, while sparing most normal cells in preclinical models. RhApo2L is being co-developed by Genentech and Amgen as a targeted therapy for solid tumors and hematologic malignancies. The present study was designed to assess the safety and PK of intravenous rhApo2L administered for the first time to humans, comparing safety in patients with liver metastasis to those without. Methods: RhApo2L was administered to patients with advanced solid tumors or NHL for 5 consecutive days every three weeks up to 8 cycles at dose levels of 0.5, 1.5, 4, 8, and 15 mg/kg. Patients without liver metastasis were treated before patients with liver metastasis in a staggered fashion. Results: Fifty-one adult patients have currently been enrolled and treated through 15 mg/kg. Of 36 patients with available data, the most common diagnoses were colorectal, melanoma, lung, and ovarian cancers. After 586 administered doses, there were no dose-limiting toxicities or clearly attributable toxicities. Thirty-two patients had at least one post-baseline tumor assessment with 17 (53%) having stable disease, and 13 (41%) with progression. One patient with a chondrosarcoma had a confirmed, objective partial response at 8 mg/kg. No anti-Apo2L antibodies have been detected. PK results will be presented separately. Conclusions: RhApo2L is safe and well tolerated up to 15 mg/kg. Enrollment is continuing at 8 mg/kg for expanded safety data and further dose optimization. Contribution to the standard treatment of advanced solid tumors and hematologic malignancies should be evaluated in randomized trials. [Table: see text]
A multicenter, randomized phase II study of sequential vinorelbine (V)/cisplatin (C)/bevacizumab (B) followed by docetaxel (D)/gemcitabine (G)/B versus D/C/B as a first-line therapy for advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
Authors: Athanasios Panayotis Kotsakis, Emmanouil Kontopodis, Nikolaos Vardakis, Kostas Kalbakis, Nikolaos K. Kentepozidis, Alexandros Xyrafas, Charalampos Christophyllakis, Dimitrios Mavroudis, Vassilis Georgoulias
Journal: Journal of Clinical Oncology (2012)

e18105 Background: The combination of D with G has been shown equally active compared to the platinum-based doublets, which is considered the cornerstone for the treatment of NSCLC, with a more favorable toxicity profile (Georgoulias V. Lancet 2001 357: 1478-84). Sequential therapy with four active drugs (two doublets) in NSCLC, including C, was recently investigated and attributed a promising response rate (Pallis A. Lung Cancer, 2006, 52(2): 165-71). Incorporation of B to the standard platinum-based regimen improved its clinical outcome. Aim of this trial was to compare the efficacy of sequential four drug treatment in combination with B to the standard non platinum-based regimen combined with B. Methods: Seventy-seven treatment naïve patients (pts) with stage IIIB and IV non-squamous NSCLC were randomized to receive V 60 mg/m 2 PO on day 1 and 8, C 80mg/m 2 IV on day 1 and B 15 mg/kg IVon day 1, for 3 cycles followed by D 75 mg/m 2 IV, G 1100 mg/m 2 IV and B 15 mg/kg IV, all on day 1 (Arm A) or D 75 mg/m 2 IV, C 80mg/m 2 IV and B 15 mg/kg IV on day. The cycles were repeated every 3 weeks for a total of 6 cycles. The primary endpoint of the study was response rate (RR) and the secondary outcome measures were overall survival (OS) and progression free survival (PFS). Results: Thirty-nine pts were randomized to the control arm (Arm B) and 38 pts to the sequential arm. Pt demographics were balanced in both the arms. The overall RR was 36.8% and 46.2% in arm A and B, respectively (p= 0.49). There were 3 complete responses, one in arm A. Median PFS was 6.87 and 5.53 months in arm A and B, respectively (p= 0.368). Median OS was 19.6 and 10.33, respectively (p= 0.239). The estimated 1 and 2-year survival for arm A versus B were 71.1% and 36% versus 45.3% and 28%, respectively. No statistically significant difference in the toxicity profile was observed between the 2 arms. Conclusions: Sequential treatment with four active drugs is feasible and safe. The combination attributes encouraging results compared to the standard platinum-based regimen.
Fork-tip needle biopsy versus fine-needle aspiration in endoscopic ultrasound-guided sampling of solid pancreatic masses: a randomized crossover study
Authors: Kofi W. Oppong, Noor L. H. Bekkali, John S. Leeds, Sarah J. Johnson, Manu K. Nayar, Antony Darné, Mark Egan, Paul Bassett, Beate Haugk
Journal: Endoscopy (2020)

Abstract Background A novel fork-tip fine-needle biopsy (FNB) needle has recently been introduced for endoscopic ultrasound (EUS)-guided sampling. The aim of this study was to compare the performance of fork-tip FNB histology and standard fine-needle aspiration (FNA) cytology in the diagnosis of solid pancreatic masses. Methods A randomized crossover study was performed in patients referred for EUS-guided sampling. Three passes were taken with each needle in a randomized order. Only samples reported as diagnostic of malignancy were considered positive. The primary end point was the sensitivity of diagnosis of malignancy. Secondary end points included the amount of sample obtained, ease of diagnosis, duration of tissue sampling, pathologist viewing time, and cost. Results 108 patients were recruited. Median age was 69 years (range 30 – 87) and 57 were male; 85.2 % had a final diagnosis of malignancy. There were statistically significant differences in sensitivity (82 % [95 % confidence interval (CI) 72 % to 89 %] vs. 71 % [95 %CI 60 % to 80 %]), accuracy (84 % [95 %CI 76 % to 91 %] vs. 75 % [95 %CI 66 % to 83 %]), proportion graded as a straightforward diagnosis (69 % [95 %CI 60 % to 78 %] vs. 51 % [95 %CI 41 % to 61 %]), and median pathology viewing time (188 vs. 332 seconds) (P &lt; 0.001) between FNB and FNA needles, respectively. There was no significant difference in cost between an FNB or FNA strategy. Conclusion The diagnostic performance of the fork-tip FNB needle was significantly better than that of FNA; it was associated with ease of diagnosis, shorter pathological viewing times, and was cost neutral.
Lymph node stromal CCL2 limits antibody responses
Authors: Dragos C. Dasoveanu, Hyeung Ju Park, Catherine L. Ly, William D. Shipman, Susan Chyou, Varsha Kumar, David Tarlinton, Burkhard Ludewig, Babak J. Mehrara, Theresa T. Lu
Journal: Science Immunology (2020)

Lymph node stromal CCL2 limits plasma cell survival via monocyte accumulation and reactive oxygen species and is tuned by vascular permeability.
Immune checkpoint targets on circulating epithelial cells in early and late breast cancer.
Authors: Leo Habets, Bettina Frenken, Ilham El Ghali, Wolfgang Koerber, Mahmoud Danaei, Manfred Kusche, Torsten Kroll, Katharina Pachmann
Journal: Journal of Clinical Oncology (2013)

e22201 Background: Our ongoing investigation of circulating epithelial cells(CEC) in early and late breast cancer with the MAINTRAC method (1ml blood, RBC lysis and fluorometric detection) has shown that CEC evade by hypoxia driven EMT (epithelial mesenchymal transition).We saw CEC with EMT and stemcellmarkers in early and late breast cancer. These cells can be found also in non cancer conditions. So far no differences in marker expression of CEC in cancer and noncancer conditions were found. This underlines the need for extended(e.g four color) analysis and allows searching for new promising targets like the immune checkpoint target PD-L1. Methods: We slightly adapted the basic MAINTRAC methodology to allow four color detection on the AMNIS FlowSight device.The IDEAS software allows comprehensive analysis of the populations. Beside four color analysis of single cells, TCA (tumor cell aggregates ) can be detected and characterized. The basic panel (EPCAMAF660.CD45PE,ALDH1FITC,DAPI) allows detection of living and death CEC and expression of the stemcell marker ALDH1. A second panel allows detection of other targets like PD-L1. Results: With the three color based original method the blood of 188 patients with early and 62 with late breast cancer were examined. No differences between conventional subgroups nor molecular subtype groups were found. In a large non cancer (n=256) control group we found high CEC counts in a group of patients with liver affections (mostly NAFLD). In these patients CEC showed the same marker ecpression .In late breast cancer only 60% of patients showed detctable cell counts.In patients with agressive disease (triple negative or HER2 enriched) mostly none or small CEC numbers were detectable.With our recently started (so far n=48) four color assay we detected coexpression of ALDH1 and PD-L1 which are more specific markers then CD44high or vimentin. Conclusions: Extended four color analysis on CEC allows monitoring of living CEC with stemcellmarker expression. Detection of immune checkpoint determinants like PD-L1on CEC is possible, further unraveling the biology of early and late breast cancer.
DETERMINANTS OF SERIAL LEFT VENTRICULAR DIASTOLIC FUNCTIONAL CHANGE AFTER DEVICE CLOSURE OF ATRIAL SEPTAL DEFECT
Authors: Chul Shin, Juyoung Kim, Jong-Youn Kim, Pil-Ki Min, Young Won Yoon, Byoung Kwon Lee, Bum-Kee Hong, Se-Joong Rim, Hyuck Moon Kwon, Eui-Young Choi
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF PAROXYSMAL ATRIAL FIBRILLATION ON RIGHT VENTRICULAR FUNCTION IN PATIENTS UNDERGOING MITRAL VALVE SURGERY FOR DEGENERATIVE MITRAL REGURGITATION(DMR)
Authors: Olga Kislitsina, Bonnie Kane, Kameswari Maganti, Inga Vaitenas, Akhil Narang, Jane T. Kruse, Adin-Cristian Andrei, Menghan Liu, Vera H. Rigolin, James Thomas, James L. Cox, Patrick McCarthy
Journal: Journal of the American College of Cardiology (2020)
SUCCESSFUL PREGNANCY AND DELIVERY WITH CENTRIFUGAL FLOW LEFT VENTRICULAR ASSIST DEVICE
Authors: Seyed Hamed Hosseini Dehkordi, Travis Abicht, Matthew Lippmann, Andrew Sauer, Nicholas A. Haglund, Marc R. Parrish, Jared Staab, Bhanu P. Gupta
Journal: Journal of the American College of Cardiology (2020)
Free fatty acid processing diverges in human pathologic insulin resistance conditions
Authors: Hilal Sekizkardes, Stephanie Therese Chung, Shaji Chacko, Morey W. Haymond, Megan Startzell, Mary Walter, Peter J. Walter, Marissa Lightbourne, Rebecca J. Brown
Journal: Journal of Clinical Investigation (2020)

BACKGROUND. Postreceptor insulin resistance (IR) is associated with hyperglycemia and hepatic steatosis. However, receptor-level IR (e.g., insulin receptor pathogenic variants, INSR) causes hyperglycemia without steatosis. We examined 4 pathologic conditions of IR in humans to examine pathways controlling lipid metabolism and gluconeogenesis.
Combination chemotherapy with temsirolimus and trabectedin in patients with heavily pretreated clear cell carcinoma of the ovary.
Authors: Masashi Takano, Hiroko Kouta, Naoki Sasaki, Kazuya Kudoh, Tsunekazu Kita, Ryoko Kikuchi, Katsutoshi Oda, Tomoko Goto, Kenichi Furuya, Yoshihiro Kikuchi
Journal: Journal of Clinical Oncology (2013)

e16519 Background: Clear cell carcinoma (CCC) of the ovary showed exceedingly chemo-resistant phenotype, especially in the case with recurrent or refractory to previous therapy. An inhibitor against the mammalian target of rapamycin (mTOR), temsirolimus, has been reported to be effective in renal CCC. Additionally, a marine natural product, trabectedin, had activity against recurrent ovarian cancers. We evaluated the effect of combination therapy with temsirolimus and trabectedin for patients with recurrent/refractory CCC of the ovary. Methods: Patients with recurrent/refractory CCC of the ovary were treated with weekly regimen using two drugs: 10mg/m 2 of temsirolimus and 0.15mg/m 2 of trabectedin (3 weeks, one week rest) with written informed consents. Treatment was continued until development of progressive disease (PD) or unmanageable adverse effects. Responses were evaluated by RECIST criteria, and adverse effects were analyzed by NCI-CTCAE v4.0. Results: A total of 12 patients treated with the regimen, and there were no cases that discontinued the therapy due to toxicities. Median age was 60 years (range: 42-69), and median number of previous chemotherapy was 3 (range: 1-5). All cases were assessable by RECIST and CTCAE. One patient (8%) had a complete response (CR), and another (8%) achieved a partial response (PR), and 4 patients (33%) had stable disease (SD) beyond three months, resulting in clinical benefit rate (CBR; CR+PR+SD&gt;3month) of 50%. Median response duration in CBR case was 3.5 months (range: 3-12+). There were no cases that developed toxicities more than grade2. Conclusions: The present preliminary study demonstrated combination therapy with temsirolimus and trabectedin was effective in patients with recurrent/refractory CCC of the ovary. These results warrant further study in such clinical settings.
INCREMENTAL VALUE OF GLS FOR CLASSIFICATION OF PROGNOSIS IN PATIENTS WITH ADVANCED LIGHT CHAIN (AL) AMYLOIDOSIS
Authors: Omar Nahhas, Katherine Lee Chuy, Ji Can Yang, Heather Landau, Heather Drill, Hani Hassoun, Carol L. Chen, Anthony F. Yu, Richard M. Steingart, Jennifer E. Liu
Journal: Journal of the American College of Cardiology (2020)
Efficacy of scalp cryotherapy in preventing alopecia among patients with breast cancer patients receiving adjuvant docetaxel and cyclophosphamide.
Authors: Tessa Cigler, Barbara Fiederlein, Sarah E. Schneider, Ellen Chuang, Linda T. Vahdat, Diana Donovan, Roberto Welch, Marta E. Cobham, Anne Moore
Journal: Journal of Clinical Oncology (2013)

e20641 Background: Chemotherapy induced alopecia (CIA) is a distressing adverse effect of many chemotherapy agents. The TC chemotherapy regimen (four cycles of docetaxel 75mg/m2 and cyclophosphamide 600mg/m2 given every 3 weeks apart) commonly used for aduvant therapy of breast cancer is associated with complete alopecia, with rare reports of permanent alopecia. Scalp cryotherapy has been reported to minimize or prevent CIA. Penguin cold caps are a commercially available scalp cooling product gaining increasing media attention. We conducted a prospective study aimed to assess efficacy of scalp cryotherpy in preventing CIA among women receiving adjuvant TC chemotherapy for early stage breast cancer who independently elected to use Penguin cold caps. Methods: Women at the Weill Cornell Breast Center who elected to use scalp cryotherapy with Penguin cold caps during adjuvant TC chemotherapy were asked to participate in the study. Degree of hair loss was rated by practitioner assessment using Dean’s alopecia scale (poor (&gt;75% hair loss), moderate (50-75%), good (25-50%) or excellent (&lt;25%)), by digital photographs, and by asking patients whether they felt a need to wear a wig or head covering due to hair loss. Assessments were made before each chemotherapy treatment and at a follow up visit between 3 weeks and 3 months after the completion of chemotherapy. Results: 17 patients have enrolled. 13 patients have completed chemotherapy. 2 patients currently undergoing chemotherapy and 2 patients who discontinued chemotherapy due to toxicity not related to alopecia are excluded from analysis. Dean’s alopecia scale score was excellent for 10 patients (77%) at every assessment. Dean’s score was good for 2 participants (15%) and moderate for 1 participant (8%) starting prior to fourth cycle of chemotherapy. Only 1 patient (8%) reported needing to wear a wig or head covering as a result of alopecia. Conclusions: Scalp cryotherapy using Penguin cold caps appears to be effective in preventing CIA among women undergoing chemotherapy with the TC regimen.
Antibiotic prescribing in primary care for end-of-life cancer patients.
Authors: Wei Gao, James F. Spicer, Irene Higginson
Journal: Journal of Clinical Oncology (2013)

9627 Background: There is ongoing debate on whether it is appropriate to administer anti-infection medications to patients approaching end of life. Population-based epidemiologic data on current antibiotic prescribing status is needed to shed lights on this issue. Methods: A population-based retrospective cohort study, based on data extracted from the General Practice Research Database (GPRD). Patients (N=29,810) with one of five major cancers (lung, colorectal, breast, prostate, head and neck), and who died in 2000-2008 were included for this analysis. Prescriptions of antibiotics(BNF codes: 5.1.1-5.1.13) for individual patients in the last 3 months of life were reviewed and analysed. The outcome was with (1) or without (0) antibiotic prescriptions. A Generalized Estimating Equation (GEE) logistic regression model was used to assess for the associations between outcome and explanatory variables. Results: Overall, 26.8% of patients(95%CI: 26.3-27.3%) had been prescribed antibiotics. There was an increasing trend in antibiotic prescribing for end-of-life cancer patients, rising from 23.2%(21.5-24.9%) in 2000 to 29.5%(28.0-31.0%) in 2008 (p&lt;0.001). Patients with the following characteristics were more likely to be prescribed antibiotics(p&lt;0.001): being younger(&lt;70:ORs 1.14-1.27) vs 80+, male gender(OR: 1.10; 1.03-1.18), lung &amp; head &amp; neck cancer(ORs:1.50-2.00) vs colorectal cancer, higher co-morbidity score(ORs vs 0-3:1.02-1.19), smoking(OR vs non-smoking 1.17;1.07-1.27), living in Northern Ireland(OR:1.43; 1.17-1.75) and Scotland(ORs: 1.23; 1.03 to 1.47) vs London. No difference by whether they drank alcohol or social economic status. Conclusions: Antibiotic prescribing at the end of life was common and increasing over the years. Further studies need to investigate clinical conditions associated with antibiotic prescribing to inform clinical practices and end of life care policy.
RIGHT VENTRICLE TO PULMONARY CIRCULATION COUPLING IS PRIMARILY DEFINED BY THE CIRCUMFERENTIAL RIGHT VENTRICLE FUNCTION
Authors: Francesco Bandera, Giacomo D’Alesio, Greta Ghizzardi, Maurizio Losito, Sara Boveri, Eleonora Alfonzetti, Marco Guazzi
Journal: Journal of the American College of Cardiology (2020)
ELEVATED BODY MASS INDEX IN THE ADULT FONTAN POPULATION: CLINICAL FEATURES AND OUTCOMES
Authors: Vidhushei Yogeswaran, Christopher Anigwe, Sarah Blissett, Anika Aggarwal, Anita Moon Grady, Elyse Foster, Vaikom S. Mahadevan, Ian Stewart Harris, Anushree Agarwal
Journal: Journal of the American College of Cardiology (2020)